Cantor Fitzgerald Raises Collegium Pharmaceutical (NASDAQ:COLL) Price Target to $30.00

Collegium Pharmaceutical (NASDAQ:COLL) had its target price upped by Cantor Fitzgerald from $24.00 to $30.00 in a research note issued to investors on Friday, BenzingaRatingsTable reports. The brokerage currently has an overweight rating on the specialty pharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on COLL. HC Wainwright upped their price target on Collegium Pharmaceutical from $25.00 to $29.00 and gave the stock an in-line rating in a report on Wednesday, January 8th. Needham & Company LLC upped their price target on Collegium Pharmaceutical from $36.00 to $38.00 and gave the stock a buy rating in a report on Friday. Zacks Investment Research upgraded Collegium Pharmaceutical from a hold rating to a buy rating and set a $25.00 price target on the stock in a report on Thursday, January 9th. ValuEngine downgraded Collegium Pharmaceutical from a buy rating to a hold rating in a report on Tuesday, January 7th. Finally, BidaskClub downgraded Collegium Pharmaceutical from a hold rating to a sell rating in a report on Saturday, February 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $29.50.

COLL opened at $23.20 on Friday. The stock’s 50-day moving average price is $21.42 and its 200 day moving average price is $15.80. Collegium Pharmaceutical has a 12-month low of $10.01 and a 12-month high of $25.59. The company has a current ratio of 1.24, a quick ratio of 1.20 and a debt-to-equity ratio of 0.22. The firm has a market cap of $853.26 million, a price-to-earnings ratio of -68.23, a PEG ratio of 2.94 and a beta of 0.81.

In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 295,287 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $21.93, for a total transaction of $6,475,643.91. Following the sale, the director now owns 402,086 shares in the company, valued at approximately $8,817,745.98. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Scott Dreyer sold 1,321 shares of the company’s stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $23.87, for a total value of $31,532.27. Following the sale, the executive vice president now owns 35,716 shares in the company, valued at approximately $852,540.92. The disclosure for this sale can be found here. 8.08% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Globeflex Capital L P increased its holdings in shares of Collegium Pharmaceutical by 2.2% in the 4th quarter. Globeflex Capital L P now owns 86,930 shares of the specialty pharmaceutical company’s stock valued at $1,789,000 after acquiring an additional 1,854 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Collegium Pharmaceutical by 12.7% in the 4th quarter. Acadian Asset Management LLC now owns 254,842 shares of the specialty pharmaceutical company’s stock valued at $5,244,000 after acquiring an additional 28,754 shares during the last quarter. State Street Corp increased its holdings in shares of Collegium Pharmaceutical by 4.2% in the 4th quarter. State Street Corp now owns 725,163 shares of the specialty pharmaceutical company’s stock valued at $14,924,000 after acquiring an additional 29,126 shares during the last quarter. Hancock Whitney Corp purchased a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at about $344,000. Finally, Swiss National Bank increased its holdings in shares of Collegium Pharmaceutical by 3.2% in the 4th quarter. Swiss National Bank now owns 51,200 shares of the specialty pharmaceutical company’s stock valued at $1,054,000 after acquiring an additional 1,600 shares during the last quarter. Institutional investors and hedge funds own 89.78% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Featured Article: What are some reasons analysts would give stocks a buy rating?

Receive News & Ratings for Collegium Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Collegium Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.